Marijuana Users May Be More Likely to Survive Acute Heart Failure Hospitalization Steve Stiles Medscape Medical News © 2019 , September 16, 2019 PHILADELPHIA — There's sunny news, potentially, for patients with heart failure who are keen on cannabis. Hospitalized patients with a primary diagnosis of acute heart failure (HF) who say they are marijuana users are more likely to survive to discharge than nonusers, and they stay fewer days at less cost to the hospital, an observational study suggests. It may be only patients with heart failure and reduced ejection fraction (HFrEF) who benefit, not those with heart failure and preserved ejection fraction (HFpEF), [...]
Lire la suiteRenseignements destinés aux professionnels de la santé : Le cannabis (marijuana, marihuana) et les cannabinoïdes (Version PDF - 2,690 Ko) https://www.canada.ca/fr/sante-canada/services/drogues-medicaments/cannabis/renseignements-medecins/renseignements-destines-professionnels-sante-cannabis-cannabinoides.html Santé Canada Auteur : Hanan Abramovici Ph.D. Co-auteurs : Sophie-Anne Lamour, Ph.D. et George Mammen, Ph.D. Nous republions cet excellent document de Santé Canada, et surtout, le résumé des indications reconnues, et envisagées, du cannabis thérapeutique. Aperçu des énoncés récapitulatifs Les énoncés récapitulatifs suivants visent à résumer le contenu des sections 4.0 (Usages thérapeutiques possibles) et 7.0 (Effets indésirables) et leurs sous-sections respectives. Les énoncés récapitulatifs peuvent être également trouvés dans leurs sections et sous-sections respectives dans le corps même du document. Remarque: la plupart des études [...]
Lire la suiteThe Past and Future of Psychedelic Science : An Introduction to This Issue Richard E. Doblin, Merete Christiansen, Lisa Jerome, Brad Burge JOURNAL OF PSYCHOACTIVE DRUGS, 2019, VOL. 51, NO. 2, 93–97 https://doi.org/10.1080/02791072.2019.1606472 ABSTRACT Psychedelic plants and fungi have been used in indigenous medicinal traditions for millennia. Modern psychedelic research began when Albert Hofmann first synthesized lysergic acid diethylamide (LSD-25) in 1938. Five years later, became the first person to ingest LSD. Hofmann was unaware of the significance of his actions, and the effects they would set in motion. After a burgeoning period of scientific and cultural exploration in the1950s and ‘60s, psychedelic research was [...]
Lire la suiteCan Psychedelic Drugs Attenuate Age-Related Changes in Cognition and Affect ? Jacob S. Aday, Emily K. Bloesch, & Christopher C. Davoli Journal of Cognitive Enhancement, August 2019 DOI: 10.1007/s41465-019-00151-6 Abstract Older adulthood can be characterized by various cognitive and affective changes. In general, older adults show declines in creativity and executive functioning. They also score lower in openness to experience, empathy, and many suffer from a paucity of meaningful experiences. Further, depression, pessimism, and suicide can be major concerns for this population. Although currently there are few interventions that can effectively address these changes, recent findings from psychedelic science suggest myriad parallels between the effects [...]
Lire la suiteClinicians’ Guide to Cannabidiol and Hemp Oils Harrison J. VanDolah, Brent A. Bauer, and Karen F. Mauck Mayo Clinic Proceedings, 2019, 94, (9), 1840-1851 https://doi.org/10.1016/j.mayocp.2019.01.003 Abstract Cannabidiol (CBD) oils are low tetrahydrocannabinol products derived from Cannabis sativa that have become very popular over the past few years. Patients report relief for a variety of conditions, particularly pain, without the intoxicating adverse effects of medical marijuana. In June 2018, the first CBD-based drug, Epidiolex, was approved by the US Food and Drug Administration for treatment of rare, severe epilepsy, further putting the spotlight on CBD and hemp oils. There is a growing body of preclinical and [...]
Lire la suite2018 : A Watershed Year for Psychedelic Science ? Jacob S. Aday, Christopher C. Davoli, & Emily K. Bloesch Article, ·August 2019 DOI: 10.1177/2050324519872284 Abstract While interest in the study of psychedelic drugs has increased over much of the last decade, in this article we argue that 2018 marked the true turning point for the field. Substantive advances in the scientific, public, and regulatory communities in 2018 significantly elevated the status and long-term outlook of psychedelic science, particularly in the United States. Advances in the scientific community can be attributed to impactful research applications of psychedelics as well as acknowledgement in preeminent journals. In the [...]
Lire la suitePsychiatric Practice Patterns and Barriers to the Adoption of Esketamine Samuel T. Wilkinson, David H. Howard, Susan H. Busch JAMA Published online August 2, 2019 doi:10.1001/jama.2019.10728 Major depressive disorder (MDD) affects approximately 17.3 million adults in the United States,1 with a 12-month and lifetime prevalence of 10.4% and 20.6%, respectively.2 Conducting clinical trials and developing new treatments for depression can be difficult because of spontaneous recovery rates and placebo effects.3 In addition, many patients with chronic and refractory MDD do not experience clinical improvement even after several treatment courses. There is growing interest in the use of exercise and improved nutrition to treat depression,4 [...]
Lire la suitePsilocybine mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects SMIGIELSKI Lukasz, SCHEIDEGGER Milan, KOMETER Michael, VOLLENWEIDER Franz X. NeuroImage, 2019, 196, 207-215 Doi : 10.1016/j.neuroimage.2019.04.009 A B S T R A C T Both psychedelics and meditation exert profound modulatory effects on consciousness, perception and cognition, but their combined, possibly synergistic effects on neurobiology are unknown. Accordingly, we conducted a randomized, double-blind, placebo-controlled study with 38 participants following a single administration of the psychedelic psilocybin (315 μg/kg p.o.) during a 5-day mindfulness retreat. Brain dynamics were quantified directly pre- and post-intervention by functional magnetic resonance imaging during the resting state and [...]
Lire la suiteThe association between cannabis use and psychiatric comorbidity in people with personality disorders : A population-based longitudinal study Nadav Shalita, Jürgen Rehmb, Shaul Lev-Ran Psychiatry Research, 2019, 278, 70–77 https://doi.org/10.1016/j.psychres.2019.05.041 A B S T R A C T Both personality disorders (PD) and cannabis use are highly comorbid with various psychiatric disorders. While previous research indicates specific interactions between cannabis use and schizotypal PD associated with schizophrenia, research into cannabis use among individuals with other PDs and the development of several additional psychiatric disorders is scarce. We explored the prevalence and incidence of psychiatric disorders among individuals with PDs who use cannabis, and whether individuals [...]
Lire la suiteAcute effects of delta-9-tetrahydrocannabinol (THC) on resting state brain function and their modulation by COMT genotype Matthijs G. Bossong, Hendrika H. van Hell, Chris D. Schubart, Wesley van Saane, Tabitha A. Iseger, Gerry Jager, Matthias J.P. van Osch, J. Martijn Jansma, René S. Kahn, Marco P. Boks, Nick F. Ramsey European Neuropsychopharmacology, 2019, 13, 56, 1–11 https://doi.org/10.1016/j.euroneuro.2019.03.010 Abstract Cannabis produces a broad range of acute, dose-dependent psychotropic effects. Only a limited number of neuroimaging studies have mapped these effects by examining the impact of cannabis on resting state brain neurophysiology. Moreover, how genetic variation influences the acute effects of cannabis on resting state brain function [...]
Lire la suite